CTS successfully implemented Donor-Screen HLA® Class I and II testing on the Stratec Biomedical AG Gemini on Monday, April 29th. As previously communicated, the Immucor assay and sample requirements are the same, and the package insert has been modified to state the assay is specific to the Stratec Gemini instrument. The new package insert, assay history list, and platform history list are now available on our website.
On May 9, 2019 the Food and Drug Administration issued a “Recommendations for Reducing the Ris...
Josh Moon has been appointed Chief Operating Officer (COO) at Creative Testing Solutions (CTS), effe...
CTS received notification from Sanochemia Pharmazeutika AG of their intent to immediately discontinu...
CTS lab staff recently participated in a Kaizen and determined emailed Daily Shipment Schedules to b...
On July 6, 2018 the FDA released an industry guidance document for transitioning from individual to ...
An exciting enhancement is implementing January 20, 2020 in our Special Testing laboratory as we mov...